<DOC>
	<DOCNO>NCT00158847</DOCNO>
	<brief_summary>The hypothesis test study treatment fluticasone propionate lead initial improvement symptom , quality life lungfunction reduction airways hyperresponsiveness . The continued decline lungfunction COPD may influence long last treatment . Addition salmeterol augment initial benefit fluticasone without change longterm decline lungfunction .</brief_summary>
	<brief_title>Modification Of Disease Outcome In COPD</brief_title>
	<detailed_description>Aim The primary aim study investigate whether short-term treatment inhaled corticosteroid COPD result great improvement airway pathology , thereby lead large clinical benefit , continuous long-term treatment . To end , outcome variable include feature airways inflammation remodelling well clinical symptom , exacerbation , quality life , decline FEV1 , bronchial responsiveness , pharmaco-economics . The secondary aim study examine histopathological clinical benefit combine treatment inhale steroid long-acting ß2-agonist COPD . Methods Patients . Patients COPD ( 45-75 yr , &gt; 10 pckyr ) use inhaled steroid past 3 month recruit . Design . In prospective , longitudinal , double blind , 4-arm study , patient follow 2.5 year ( Figure 1 ) . They treat high dose inhale corticosteroid ( 500 g fluticasone bid ) , combine inhaled steroids+long-acting ß2-agonist ( 500 µg fluticasone+50 µg salmeterol ) placebo 6 month . Half patient steroid group continue treatment steroid another 2 year , whereas half received placebo . The combination therapy placebo group remain unaltered treatment 2.5 year . Measurements . Symptoms , exacerbation , QOL questionnaires spirometry monitor every 3 month . Peripheral blood eosinophil , IgE , exhale NO , bodyplethysmography , CO-diffusion capacity , PC20 methacholine , sputum induction bronchoscopy perform 0 , 6 , 30 month . In BAL induce sputum measure cell differential state activation . Immunohistochemistry perform bronchial biopsy specimen , stain marker infiltrative resident cell , morphometric analysis allow airway remodelling quantify , use computerized image analysis system . The effect treatment analyze relate observe change clinical pathophysiological outcome , cellular histological outcome use linear mixed statistical model .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Inclusion criterion : COPD patient &gt; 10 pack year . Written informed consent . Able complete diary card . At least one follow symptom : chronic cough , chronic sputum production , frequent exacerbation , dyspnoea exertion . Postbronchodilator FEV1 90 % confidence interval predict postbronchodilator FEV1/FVC 90 % confidence interval predict . Exclusion criterion : No oral corticosteroid 3 month prior study maintenance treatment corticostroids 6 month prior study . No history asthma , lung disease COPD , diseases likely interfere study .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2005</verification_date>
	<keyword>COPD inflammation sputum lung function biopsy</keyword>
</DOC>